radiolabeled anti-CEACAM6 antibodies (NIH)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug Nameradiolabeled anti-CEACAM6 antibodies (NIH)
Drug Alias Name64Cu-DOTA-2A3-mFc
ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionPositron-emission tomography enhancers
TargetsUpdating
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A